A/Prof Luc Furic
Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology
134 Scholarly works
6 Projects
HIGHLIGHTS
2026
Journal article
Recurrent intra-tumour heterogeneity is a hallmark of metastatic prostate cancer.
DOI: 10.1038/s41467-026-74334-z2026
Journal article
Abstract SY24-02: Di-codon organization links tRNA modifications to cancer cell proteome composition
DOI: 10.1158/1538-7445.am2026-sy24-022026
Journal article
Abstract 427: PMR-116, a second-generation RNA polymerase I inhibitor displaying therapeutic efficacy in a broad spectrum of malignancies.
DOI: 10.1158/1538-7445.am2026-4272026
Journal article
Abstract 601: Translational reprogramming disrupts mitosis to drive SMAD4-deficient esophageal adenocarcinoma.
DOI: 10.1158/1538-7445.am2026-6012023
Research grants (international)
An Accelerated Platform Using Lead-212 Targeted \03b1-Particle Therapy to Radically Improve Cancer Lethality of Prostate Cancer Theranostics Using Novel Targets and Better Understanding of Resistance: The Cancer Lethality Lead Collaboration
2023
Research grants (ARC, NHMRC, MRFF)
Codon Bias and the Role of tRNA Modifications in Cancer
2023
Research grants (ARC, NHMRC, MRFF)
Exploiting tRNA-dependent Translational Deregulation for Cancer Treatment
RECENT SCHOLARLY WORKS
2025
Journal article
Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial
DOI: 10.1016/S1470-2045(25)00559-52025
Journal article
Abstract PR-02: Loss of tumor-intrinsic type I IFN facilitates and predicts bone-metastatic progression in advanced prostate cancer and drives radiotherapeutic resistance
DOI: 10.1158/2326-6074.cimm25-pr-022025
Journal article
77P PMR-116, a second generation ribosome biogenesis inhibitor, displays antitumour activity in a wide range of preclinical cancer models and on-target activity in a phase I trial
DOI: 10.1016/j.esmoop.2025.1054272025
Journal article
First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study
DOI: 10.1016/S1470-2045(25)00332-82024
Journal article
Editorial Expression of Concern: Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer.
DOI: 10.1038/s41388-024-03158-22024
Journal article
Correction: Editorial Expression of Concern: Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer.
DOI: 10.1038/s41388-024-03204-z
RECENT PROJECTS
2026
Research grants (other domestic)
Trouble at the Ribosome in C9orf72-Driven Amyotrophic Lateral Sclerosis
2022
Research grants (international)
PMR-116, a Novel Inhibitor of Ribosome Biogenesis With Antitumor Activity in Preclinical Models of Prostate Cancer